SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
出版年份 2021 全文链接
标题
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
作者
关键词
-
出版物
Cardiovascular Diabetology
Volume 20, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-02-12
DOI
10.1186/s12933-021-01243-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases
- (2021) Charles Khouri et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Atrial Fibrillation
- (2021) Gregory F. Michaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
- (2020) Salva R. Yurista et al. Cardiovascular Diabetology
- Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial
- (2020) Thomas A. Zelniker et al. CIRCULATION
- Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
- (2020) Benedetta Maria Bonora et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database
- (2020) Putkaradze Zaza et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction
- (2020) Xiaodong Peng et al. Frontiers in Physiology
- SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
- (2020) Wen-jie Li et al. Cardiovascular Diabetology
- Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK
- (2020) Ling Xiao et al. CIRCULATION
- Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials
- (2020) Victor Okunrintemi et al. DIABETES OBESITY & METABOLISM
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease
- (2020) Basile Chrétien et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus
- (2019) David D. Berg et al. CIRCULATION
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
- (2019) Qingmiao Shao et al. Cardiovascular Diabetology
- Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
- (2019) Gian Paolo Fadini et al. BMJ Open Diabetes Research & Care
- Observational research on sodium glucose co-transporter 2 inhibitors: a real breakthrough?
- (2018) Emanuel Raschi et al. DIABETES OBESITY & METABOLISM
- Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems
- (2018) E. Raschi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
- (2018) Gian Paolo Fadini et al. Diabetes Therapy
- Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
- (2018) Gian Paolo Fadini et al. Diabetes Therapy
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data
- (2016) Mayur Sarangdhar et al. NATURE BIOTECHNOLOGY
- A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases
- (2015) Mickael Arnaud et al. DRUG SAFETY
- Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies
- (2015) Christos A. Goudis et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records
- (2012) M. Liu et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Meta-Analysis of Cohort and Case–Control Studies of Type 2 Diabetes Mellitus and Risk of Atrial Fibrillation
- (2011) Rachel R. Huxley et al. AMERICAN JOURNAL OF CARDIOLOGY
- Chronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation
- (2011) Alvaro Alonso et al. CIRCULATION
- Prevention of Atrial Fibrillation
- (2009) Emelia J. Benjamin et al. CIRCULATION
- Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation
- (2009) G. A. Nichols et al. DIABETES CARE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now